RESUMEN
AIM: The aim of this study is to determine whether cardiotoxin III (CTX III) inhibited the metastasis in MDA-MB-231 cells and to further explain its possible mechanisms. MAIN METHODS: The MTT assay, wound healing assay, Boyden chamber invasion assay, zymography analysis, reverse transcriptase polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), inhibitor assay, and Western blot analysis were used to reveal molecular events of CTX III in this study. KEY FINDINGS: During treatment with non-toxic doses of CTX III, not only cell migration and invasion were markedly suppressed but the expression/activity of matrix metalloproteinase-9 (MMP-9) was also significantly and selectively suppressed in a concentration-dependent manner. In addition, CTX III decreased the nuclear protein level of nuclear factor kappa B (NF-κB), and pretreatment with NF-κB inhibitor (PDTC) or IκB protease inhibitor (TPCK) also reduced MMP-9 expression/activity and cell migration. Our biochemical assays indicated that CTX III potently suppressed the phosphorylation of p38 mitogen-activated protein kinase (MAPK), phosphatidylinositide-3-kinase (PI3K) and Akt. Additionally, the treatment of inhibitors specific for p38 MAPK (SB203580) or PI3K (wortmannin) to cells could result in a reduced expression of NF-κB and MMP-9 expression, concomitantly with an inhibition on cell metastasis. SIGNIFICANCE: These results demonstrated that CTX III inhibition of MDA-MB-231 cells may occur through inactivation of both PI3K/Akt and p38 MAPK signaling pathways, exerting inhibitory effects on NF-κB transcriptional factor, thereby decreasing the activity of MMP-9 and then posing an anti-metastatic effect in the cells.
Asunto(s)
Antineoplásicos/farmacología , Neoplasias de la Mama/enzimología , Proteínas Cardiotóxicas de Elápidos/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Inhibidores de las Quinasa Fosfoinosítidos-3 , Proteínas Proto-Oncogénicas c-akt/antagonistas & inhibidores , Proteínas Quinasas p38 Activadas por Mitógenos/antagonistas & inhibidores , Animales , Antineoplásicos/aislamiento & purificación , Antineoplásicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Proteínas Cardiotóxicas de Elápidos/uso terapéutico , Femenino , Humanos , Sistema de Señalización de MAP Quinasas/fisiología , Fosfatidilinositol 3-Quinasas/fisiología , Proteínas Proto-Oncogénicas c-akt/fisiología , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismoRESUMEN
Cardiotoxin III (1), a basic polypeptide with 60 amino acid residues isolated from Naja naja atra venom, has potential therapeutic activity in cancer. Treatment with 1 reduced phosphorylation of EGFR and Akt, as well as ERK in Ca9-22 cells. Moreover, 1-treatment inhibited constitutive activation of STAT3 and STAT5 in a time-dependent manner. Up-regulation of Bax and down-regulation of anti-apoptotic proteins including Bcl-2, Bcl-X(L), and myeloid cell leukemia-1(Mcl-1) were also found in cells treated with 1. In addition, 1-treatment disrupted mitochondrial membrane potential (DeltaPsim) and resulted in release of mitochondrial cytochrome c and activation of both caspases-9 and -3. AG1478, a specific pharmacological inhibitor of EGFR activation, mimics the cytotoxic effects of 1. Taken together, these results showed that 1 causes significant induction of apoptosis in Ca9-22 cells via abolition of the EGFR-mediated survival pathway of these cells. Thus, cardiotoxin III appears to be a potential therapeutic agent for killing oral squamous carcinoma Ca9-22 cells.
Asunto(s)
Antineoplásicos/uso terapéutico , Carcinoma de Células Escamosas/tratamiento farmacológico , Proteínas Cardiotóxicas de Elápidos/uso terapéutico , Venenos Elapídicos/uso terapéutico , Receptores ErbB/efectos de los fármacos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Antineoplásicos/farmacología , Proteínas Cardiotóxicas de Elápidos/farmacología , Venenos Elapídicos/farmacología , Receptores ErbB/metabolismo , Humanos , Fosforilación/efectos de los fármacos , Conformación Proteica , Proteínas Proto-Oncogénicas c-akt/efectos de los fármacos , Quinazolinas , Tirfostinos/farmacologíaRESUMEN
Cardiotoxin III (CTX III), a basic polypeptide with 60 amino acid residues isolated from Naja naja atra venom, has been reported to have anticancer activity. The molecular effects of CTX III on HL-60 cells were dissected in the present study. We found that the antiproliferative action of CTX III on HL-60 cells was mediated through apoptosis, as characterized by an increase of sub G1 population, DNA fragmentation and poly(ADP-ribose) polymerase (PARP) cleavage. Upregulation of Bax, downregulation of Bcl-2, the release of mitochondrial cytochrome c to cytosol and the activations of capase-9 and -3 were noted, while CTX III had no appreciable effect on the levels of Bcl-X(L) and Bad proteins. Moreover, c-Jun N-terminal kinase (JNK) was activated shortly after CTX III treatment in HL-60 cells. Consistently, the SP600125 compound, an anthrapyrazolone inhibitor of JNK, suppressed apoptosis induced by CTX III. As expected, this JNK inhibitor also attenuated the modulation of Bax and Bcl-2, as well as the cytosolic appearance of cytochrome c and the activation of caspase-3 and caspase-9 that induced by CTX III. These findings suggest that CTX III can induce apoptosis in HL-60 cells via the mitochondrial caspase cascade and the activation of JNK is critical for the initiation of the apoptotic death of HL-60 cells.
Asunto(s)
Apoptosis/fisiología , Proteínas Cardiotóxicas de Elápidos/fisiología , Proteínas Quinasas JNK Activadas por Mitógenos/fisiología , Leucemia Promielocítica Aguda/enzimología , Leucemia Promielocítica Aguda/patología , Antineoplásicos/uso terapéutico , Apoptosis/efectos de los fármacos , Proteínas Cardiotóxicas de Elápidos/uso terapéutico , Activación Enzimática/fisiología , Células HL-60 , Humanos , Leucemia Promielocítica Aguda/tratamiento farmacológicoRESUMEN
La oclusión aguda de la arteria renal es una entidad que requiere, para su diagnóstico, un alto grado de sospecha clínica, siendo muy difícil su diagnóstico en vida y bastante frecuente como hallazgo en la autopsia. Clásicamente las enfermedades cardiológicas, como la fibrilación auricular, la estenosis mitral y la endocarditis, entre otras, son factores de riesgo potencial para la embolización periférica, habiéndose descrito ésta a diferentes niveles cerebral, miembros inferiores, mesentérica, esplénica y renal. El infarto renal se produce cuando una arteria renal principal es ocluida por un émbolo o trombo, siendo la clínica muy inespecífica, dolor lumbar, fiebre, náuseas, etc., al igual que la alteración analítica que puede mostrar leucocitosis, proteinuria, hematuria. El tratamiento clásico propuesto es la revascularización quirúrgica, aunque es posible la disolución del coágulo mediante la perfusión de agentes trombolíticos (AU)
Asunto(s)
Femenino , Persona de Mediana Edad , Humanos , Reperfusión/métodos , Reperfusión , Isquemia/diagnóstico , Isquemia/terapia , Isquemia/complicaciones , Terapia Trombolítica/métodos , Fibrilación Atrial/complicaciones , Fibrilación Atrial/diagnóstico , Fibrilación Atrial/terapia , Angiografía/métodos , Angiografía , Tomografía Computarizada de Emisión/métodos , Tomografía Computarizada de Emisión , Proteínas Cardiotóxicas de Elápidos/uso terapéuticoRESUMEN
A phase I study was performed to evaluate the maximum tolerated dose (MTD), safety profile and pharmacokinetic data with VRCTC-310, a natural product derived from purified snake venom fractions, with phospholipase A2 activity and inhibitory effects against human and murine tumor cell lines. Fifteen patients with refractory malignancies were entered after providing written informed consent. VRCTC-310 was administered as an intramuscular injection daily for 30 consecutive days. Doses were escalated from 0.0025 to 0.023 mg/kg. Toxicities included local pain at the injection site, eosinophilia, reversible diplopia and palpebral ptosis. Dose escalation was stopped at 0.023 mg/kg, when two patients had developed anaphylactoid reactions. Both cases had high VRCTC-310-specific IgG by EIA. MTD was 0.017 mg/kg and the recommended dose for phase II studies is 0.017 mg/kg. Stabilization was found in six patients.